U.S. Physical Therapy, Inc.

Fundamentals6.0
Price Action6.0
News Sentiment6.0
AI Rating
6.0

Key Drivers

  • Strong free cashflow
  • Thin liquidity
  • High intangibles

AI
AI Summary

6.0

USPH's shift into minority/partnered M&A and IIP/RTM/tech initiatives meaningfully changes the valuation framework—investors should explicitly value optionality from these growth levers while treating execution, integration and refinancing/leverage risk as the primary downside triggers to the current premium multiple.

Optionality
ExecutionRisk
Leverage‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • Strong free cashflow
  • Thin liquidity
  • High intangibles

USPH posts solid margins, strong FCF and constructive ROIC but is hampered by thin liquidity, high intangibles, quarterly earnings volatility and rich valuation.

cashflow
liquidity

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Lower highs
  • Lower lows
  • Rapid pullback

The stock has trended down over the last month from mid‑February peaks into lower highs/lows, trading around $73.86 (roughly 7–8% below its last‑month average) after a ~15% drop, with resistance now at $80–$83 and support in the low‑$70s.

bearish
watchlist
Support Level: $70–$73
Resistance Level: $80–$83

~15% decline from mid‑February mid‑$80s to $73.86 on 2026‑03‑20 indicating accelerated selling

Sentiment & News

6.0

Key News Insights:

  • Adjusted EBITDA $95M
  • Analyst upgrades
  • 4D Advisors sell‑down

USPH reported FY2025 adjusted EBITDA of $95.0M and secured analyst upgrades and a $104.50 average target after Q4 results and investor outreach, although 4D Advisors sold 110k shares (~$9.34M).

AnalystUpgrade
InstitutionalSell

Analyst momentum and management outreach likely lend near‑term support to the stock, but the large institutional sale injects caution into the outlook